Home › Targets › KIT
KIT (3 companies · 8 programs)
Companies with an active program directed at KIT.
- barzolvolimab — Chronic Spontaneous Urticaria Phase 3
- barzolvolimab — Symptomatic Dermographism Phase 3
- barzolvolimab — Prurigo Nodularis Phase 2
- barzolvolimab — Atopic Dermatitis Phase 2
- barzolvolimab — Chronic Inducible Urticaria Phase 3
- bezuclastinib — Gastrointestinal Stromal Tumor NDA Submitted
- bezuclastinib — Gastrointestinal Stromal Tumors NDA Submitted
- EDP-978 — Chronic Spontaneous Urticaria Phase 1
